Choosing a flexible digital platform for drug discovery
New modalities, new tools: choosing a flexible digital platform for drug discovery (Image: Shutterstock)
With small molecule research being the dominant modality for decades, many legacy data platforms are struggling to cope with the demands of newer modalities, such as RNA therapeutics, gene therapies, ADCs (antibody drug conjugates) and protein degraders. For drug discovery teams, these new modalities are an exciting prospect, but multiple modalities throw up a range of challenges around data management. At a recent roundtable discussion, hosted by Scientific Computing World, leading drug discovery experts discussed the data impact of working with these multiple modalities, covering areas such as data standards, ontologies, cultural challenges and software needs.
This long-form white paper covers:
Managing data issues with multiple modalities
Decision-making on data structures
Encouraging collaboration among software platforms and silos
Bespoke vs public data languages and ontologies
Cultural challenges in changing data platforms and structures
Artificial intelligence (AI) and machine learning (ML) in drug discovery
How software platforms can improve
Contributors include:
- Simon Andrews, Head of Bioinformatics, The Babraham Institute
- Mattias Bood, Associate Principal Scientist, AstraZeneca
- Irene Choi, Senior Director, Head of Drug Discovery, Verge Genomics
- Nick Lynch, Director, Curlew Research
- Evelien Micholt, Operational Lead Discovery Sciences, Galapagos
- Roberto Olivares-Amaya, former VP Omics & AI, LifeMine Therapeutics
- Sarah Sirin, Director and Head of Computational Chemistry, Remix Therapeutics
- Nicolas Triballeau, Director, Drug Discovery, Revvity Signals
The white paper is ideal for those working in pharmaceutical drug discovery:
Medicinal chemists
R&D research leaders
Bioinformatics and cheminformatics professionals
IT and digital transformation leaders
Complete the form below to access this 28-page expert-led white paper, which is produced by Scientific Computing World, in partnership with Revvity Signals.
